Cas:338-61-4 3,3-Bis(Fluoromethyl)oxetane manufacturer & supplier

Chemical Name:3,3-Bis(Fluoromethyl)oxetane

CAS.NO:338-61-4

Synonyms:HT159;3,3-Bis-fluormethyl-oxetan;3,3-bis-fluoromethyl-oxetane;Oxetane, 3,3-bis(fluoromethyl)-;3,3-Bis(Fluoromethyl)oxetane

Molecular Formula:C₅H₈F₂O

Molecular Weight:122.113

HS Code:2932999099

Physical and Chemical Properties:

Melting point:N/A

Boiling point:153.3±25.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.360

PSA:9.23000

Exact Mass:122.054321

LogP:0.12

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like HT159 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,3-Bis(Fluoromethyl)oxetane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,HT159 Use and application,3,3-bis-fluoromethyl-oxetane technical grade,usp/ep/jp grade.

Related News: Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added. 3,3-Bis(Fluoromethyl)oxetane manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 3,3-Bis(Fluoromethyl)oxetane supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 3,3-Bis(Fluoromethyl)oxetane vendor They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients. 3,3-Bis(Fluoromethyl)oxetane factory They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients.